Brief: VBI Vaccines Announces Dosing Of First Patient In Second Phase 2 Study In Chronic Hepatitis B Patients As Part Of Expansion Of Clinical Collaboration With Brii Bio
05/01/2022 13:33
Jan 5 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES ANNOUNCES DOSING OF FIRST PATIENT IN SECOND
PHASE 2
STUDY IN CHRONIC HEPATITIS B PATIENTS AS PART OF EXPANSION OF
CLINICAL COLLABORATION WITH BRII BIO
* VBI VACCINES INC - INITIAL DATA FROM NEW STUDY EXPECTED IN
H1
2023
Source text for Eikon: ID:nBw4Fhy7Ma
Further company coverage: VBIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55